![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
.jpg)
Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations
CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set drug prices relative to those in the U.S., among other measures. The chief executives argued that the move is necessary to prevent the continued pivot of European drugmakers toward more lucrative biopharma markets like China and the U.S.
CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set drug prices relative to those in the U.S., among other measures. The chief executives argued that the move is necessary to prevent the continued pivot of European drugmakers toward more lucrative biopharma markets like China and the U.S.
